<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04225429</url>
  </required_header>
  <id_info>
    <org_study_id>EZH-801</org_study_id>
    <nct_id>NCT04225429</nct_id>
  </id_info>
  <brief_title>Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma</brief_title>
  <official_title>Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Epizyme, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>WEP Clinical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Epizyme, Inc.</source>
  <brief_summary>
    <textblock>
      A multicenter, open-label expanded access program to provide access to tazemetostat to&#xD;
      Epithelioid Sarcoma (ES) patients in serious need who are otherwise unable to participate in&#xD;
      a clinical study or whom access is not available through marketed product in the US.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <expanded_access_info>
    <expanded_access_type_intermediate>Yes</expanded_access_type_intermediate>
  </expanded_access_info>
  <condition>Epithelioid Sarcoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tazemetostat</intervention_name>
    <description>800mg/dose taken orally twice every day.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Patients with epithelioid sarcoma (ES) are eligible to enroll in the EAP. The patient with&#xD;
        ES must have an advanced disease that is considered life threatening at the time of&#xD;
        enrollment and appropriate, comparable, or satisfactory alternative treatments must have&#xD;
        been tried without clinical success. Patients with conditions other than ES are not&#xD;
        eligible for the tazemetostat EAP.&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          1. Age (at the time of consent): ≥18 years of age.&#xD;
&#xD;
          2. They are unable to participate in tazemetostat clinical trials for their condition.&#xD;
&#xD;
          3. Can provide signed written informed consent.&#xD;
&#xD;
          4. Morphology and immunophenotypic panel consistent with epithelioid sarcoma (e.g., CD34,&#xD;
             epithelial embrane antigen [EMA], Keratin, and INI1).&#xD;
&#xD;
          5. Female patients of childbearing potential should:&#xD;
&#xD;
               -  Agree to practice one highly effective method of contraception and one additional&#xD;
                  effective barrier method (eg, condom or diaphragm with spermicide) at the same&#xD;
                  time, from the time of providing voluntary written informed consent through 30&#xD;
                  days or 5 half-lives (whichever is longer) after the last dose of tazemetostat,&#xD;
                  and&#xD;
&#xD;
               -  Have a negative beta-human chorionic gonadotropin (β-hCG) pregnancy test at time&#xD;
                  of screening and within 14 days prior to planned first dose of tazemetostat&#xD;
                  (urine or serum test is acceptable however, positive urine tests must be&#xD;
                  confirmed with serum testing), and&#xD;
&#xD;
               -  Agree to use effective contraception from start of screening until 30 days&#xD;
                  following the last dose of tazemetostat and have a male partner who uses a&#xD;
                  condom, or&#xD;
&#xD;
               -  Practice true abstinence, (when this is in line with the preferred and usual&#xD;
                  lifestyle of the patient) or&#xD;
&#xD;
               -  Have a male partner who is vasectomized.&#xD;
&#xD;
          6. Male patients with a female partner of childbearing potential should:&#xD;
&#xD;
               -  Be vasectomized, or&#xD;
&#xD;
               -  Agree to use condoms from at least 7 days prior to initiating and during&#xD;
                  tazemetostat treatment and for at least 30 days following the last dose of&#xD;
                  tazemetostat, or&#xD;
&#xD;
               -  Have a female partner who is NOT of childbearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1. Is unwilling to exclude grapefruit juice, Seville oranges and grapefruit from the&#xD;
             diet and all foods that contain those fruits from time of enrollment while on the EAP.&#xD;
&#xD;
             2. Is currently taking any prohibited medication(s) as described in Section 6.3 of the&#xD;
             protocol.&#xD;
&#xD;
             3. Has known hypersensitivity to any of the components of tazemetostat or other&#xD;
             inhibitor(s) of EZH2.&#xD;
&#xD;
             4. Has thrombocytopenia, neutropenia, or anemia of Grade ≥3 (per CTCAE v5.0 criteria)&#xD;
             within the past month, or any prior history of myeloid malignancies, including&#xD;
             myelodysplastic syndrome (MDS).&#xD;
&#xD;
             5. Is known to have any abnormalities associated with MDS (e.g. del 5q, chr 7 abn) and&#xD;
             MPN (e.g. JAK2 V617F) observed in cytogenetic testing and DNA sequencing.&#xD;
&#xD;
             6. Has a prior history of T-LBL/T-ALL. 7. For female patients of childbearing&#xD;
             potential: Is pregnant or nursing. 8. For male patients: Is unwilling to adhere to&#xD;
             contraception criteria from at least 7 days prior to initiating and during&#xD;
             tazemetostat treatment and for at least 30 days after last dose of tazemetostat.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <link>
    <url>http://www.epizyme.com/expanded-access-policy/</url>
    <description>Epizyme's Expanded Access Policy</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 8, 2020</study_first_submitted>
  <study_first_submitted_qc>January 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2020</study_first_posted>
  <last_update_submitted>March 4, 2020</last_update_submitted>
  <last_update_submitted_qc>March 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epithelioid Sarcoma</keyword>
  <keyword>Oncology</keyword>
  <keyword>SMARC-B</keyword>
  <keyword>loss of INI 1</keyword>
  <keyword>EZH2</keyword>
  <keyword>Expanded Access</keyword>
  <keyword>Compassionate Use</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

